Ionis Pharmaceuticals, Inc., a commercial-stage biotechnology company, provides RNA-targeted medicines in the United States. The company offers TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS) and acute pancreatitis; WAINUA for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults; and SPINRAZA for pediatric and adult patients with spinal muscular atrophy (SMA). It also provides QALSODY for the treatment of Amyotrophic Lateral Sclerosis (ALS); TEGSEDI for the treatment of ATTRv-PN in adults; and WAYLIVRA for treatment for FCS and familial partial lipodystrophy. It also develops products under Phase 3 clinical trials, such as Olezarsen for patients with hypertriglyceridemia (SHTG) and cardiovascular disease (CVD); Donidalorsen for patients with hereditary angioedema; and Zilganerse, a potential treatment for people with genetically confirmed Alexander disease, as well as ION582 that has completed Phase 2 clinical trial for the potential treatment of AS, a rare genetic neurological disease. In addition, the company develops Eplontersen to degrade mutant and wild-type TTR mRNA through binding to the TTR mRNA; Pelacarsen to inhibit the production of apolipoprotein(a) in the liver to offer a direct approach for reducing lipoprotein(a); Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus; Sefaxersen to reduce the production of complement factor B and lower activation of the alternative complement pathway; and Ulefnersen to reduce the production of the fused in sarcoma, as well as other mid-stage pipeline investigational medicines. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with GSK, AstraZeneca, Novartis, and Roche, as well as with Metagenomi. The company was incorporated in 1989 and is headquartered in Carlsbad, California.

Ionis Pharmaceuticals Inc.

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Anavex Life Sciences (AVXL – Research Report), Cytok...

Analysts Are Bullish on These Healthcare Stocks: Anavex Life Sciences (AVXL), Cytokinetics (CYTK)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Progyny (PGNY – Research Report) and Ionis Pharmaceu...

Analysts Are Bullish on These Healthcare Stocks: Progyny (PGNY), Ionis Pharmaceuticals (IONS)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Healthequity (HQY – Research Report) and Ionis Pharm...

Analysts Are Bullish on Top Healthcare Stocks: Healthequity (HQY), Ionis Pharmaceuticals (IONS)

RBC Capital analyst Luca Issi maintained a Buy rating on Ionis Pharmaceuticals today and set a price target of $95.00. Issi covers the Healthcare s...

RBC Capital Keeps Their Buy Rating on Ionis Pharmaceuticals (IONS)

Cathie Wood’s ARK Invest ETFs (exchange-traded funds) made notable portfolio moves on Monday, January 12, as revealed in daily fund disclosures. Th...

Cathie Wood Doubles Down on High-Potential Biotech Plays

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on MoonLake Immunotherapeutics (MLTX – Research Report)...

Analysts Offer Insights on Healthcare Companies: MoonLake Immunotherapeutics (MLTX) and Ionis Pharmaceuticals (IONS)

Cathie Wood made several trades across her ARK ETFs on Tuesday, January 6, 2026, according to daily trade filings. The moves showed new buying in R...

Current Yield	N/A	Payout Ratio	0.00%
Annual DPS	$0.00	Growth Streak	0 years
Ex-Dividend	Invalid Date	Pay Date	Invalid Date
Frequency	NA	Quarterly Est	$0.00

	A	B	C	D
1	Symbol	Price	Change	Volume
2	IONS	$84.26	+1.43%	854.73K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	IONS	$84.26	+1.4%	854.73K
3
4
5
6

IONS

IONS

Dividend Overview

Get Ionis Pharmaceuticals Inc. Data in Excel

Get Ionis Pharmaceuticals Inc. Data in Excel